Dupixent Shows Promise as First Treatment for Childhood EoE

Data from an ongoing Phase III trial showed Sanofi/Regeneron's Dupixent (dupilumab) can induce histological disease remission in young eosinophilic esophagitis (EoE) patients ages 1–11 years, the companies announced Tuesday.